Diffuse large B-cell lymphoma trials in China

In China 133 Also abroad 346

133 trials · From ClinicalTrials.gov, checked 10 November 2026. Ask the study team whether a trial fits you.

Phase 1/2Not yet taking people in China
A Phase I/II Study of TRS005 in Combination With Cyclophosphamide, Doxorubicin, and Prednisone（T-CHP） in Previously Untreated Patients With CD20-positive DLBCL
Where
Beijing
Age
18 years and over
People
66
Run by
Zhejiang Teruisi Pharmaceutical Inc.
See details and how to joinNCT07035379
Phase 2Taking people
Pola-ZR2P in Previously Untreated DLBCL
Where
Beijing
Age
14 years and over
People
80
Run by
Navy General Hospital, Beijing
See details and how to joinNCT06664411
Phase 2Taking people
Orelabrutinib Combined With Pola-R-CHP Regimen for the Treatment of Untreated Non-GCB Diffuse Large B-Cell Lymphoma
Where
Hangzhou
Age
18 years to 80 years
People
48
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT07078500
Phase 1Enrolling by invitation
Cord Blood-derived CAR-NK Cells Targeting CD19 for Refractory/Relapsed Central Nervous System Lymphoma
Where
Hangzhou
Age
18 years to 75 years
People
42
Run by
Second Affiliated Hospital, Zhejiang University, School of Medicine
See details and how to joinNCT06827782
Phase 1/2Taking people
A Study of HDM2005 in Combination With Standard of Care in Patients With Diffuse Large B-Cell Lymphoma
Where
Beijing, Changchun, Changsha, Chengdu, Fuzhou, Guangzhou, Hangzhou, Harbin, Jinan, Kunming, Nanchang, Nanning, Shenyang, Suzhou, Taiyuan, Wuhan, Xi’an, Zhengzhou
Age
18 years to 75 years
People
97
Run by
Hangzhou Zhongmei Huadong Pharmaceutical Co., Ltd.
See details and how to joinNCT07124936
Phase 2Not yet taking people in China
Pirtobrutinib in Combination With Rituximab, Gemcitabine, Oxaliplatin With or Without Polatuzumab Vedotin in Covalent BTK Inhibitor-Pretreated Relapsed/Refractory Diffuse Large B-Cell Lymphoma
Where
Shanghai
Age
18 years and over
People
22
Run by
Ruijin Hospital
See details and how to joinNCT07122609
Phase 1/2Taking people
A Study of GFH009 in Combination With Zanubrutinib in Subjects With Relapsed or Refractory DLBCL
Where
Nanning, Zhengzhou
Age
18 years and over
People
51
Run by
Genfleet Therapeutics (Shanghai) Inc.
See details and how to joinNCT06375733
Phase 1/2Taking people
Fourth-gen CAR T Cells Targeting CD19/CD22 for Highly Resistant B-cell Lymphoma/Leukemia (PMBCL/CNS-BCL).
Where
Beijing
Age
2 years to 90 years
People
75
Run by
Essen Biotech
See details and how to joinNCT06213636
Phase 2Taking people
Large Fraction Radiation Therapy Combined With Lenalidomide, and Glofitamab in Refractory Relapsed DLBCL
Where
Xiamen
Age
18 years and over
People
22
Run by
The First Affiliated Hospital of Xiamen University
See details and how to joinNCT06651853
No phaseTaking people
Pomalidomide, Rituximab and Orelabrutinib Combined With Polatuzumab Vedotin in the Treatment of Newly Diagnosed Elderly Patients With DLBCL
Where
Suzhou
Age
70 years and over
People
43
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT07072208
No phaseTaking people
Study on Predicting Response to Standard First-Line Treatment in Diffuse Large B-Cell Lymphoma (DLBCL) Patients Using ctDNA Combined With PET
Where
Shanghai
Age
18 years and over
People
300
Run by
Fudan University
See details and how to joinNCT07070648
Phase 2Taking people
Glofitamab Bridging ASCT for Patients With Relapsed or Refractory DLBCL
Where
Suzhou
Age
18 years to 70 years
People
40
Run by
The First Affiliated Hospital of Soochow University
See details and how to joinNCT06682130
Phase 2Not yet taking people in China
A Phase II Trial of 4 vs 6 Cycles of CHP Combined With Polatuzumab Vedotin-Rituximab in Untreated DLBCL Patients With IPI 0-1
Where
Tianjin
Age
18 years to 80 years
People
134
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT07034508
Phase 2Taking people
Evaluation of the Efficacy and Safety of Polatuzumab Vedotin Combined With Rituximab, Gemcitabine, and Oxaliplatin (Pola-R-GemOx) as Salvage Therapy for Relapsed/Refractory Diffuse Large B-Cell Lymphoma (DLBCL) Patients Ineligible for Autologous Transplantation
Where
Shanghai
Age
18 years and over
People
130
Run by
Fudan University
See details and how to joinNCT07001540
Phase 2Taking people
Sintilimab Plus Rituximab Followed by R-CHOP Regimen in Untreated PMBL
Where
Fuzhou, Guangzhou
Age
18 years to 75 years
People
30
Run by
Sun Yat-sen University
See details and how to joinNCT06742502
Phase 2Taking people
GVM±R in Patients With Relapsed or Refractory Aggressive NHL.
Where
Tianjin
Age
18 years to 65 years
People
115
Run by
Institute of Hematology & Blood Diseases Hospital, China
See details and how to joinNCT06244368
Phase 2Taking people
Study to Evaluate Efficacy and Safety of Oral Abexinostat in Patients With Relapsed or Refractory Diffuse Large B-cell Lymphoma (DLBCL)
Where
Beijing, Chengdu, Dalian, Fuzhou, Guangzhou, Hangzhou, Harbin, Lanzhou, Linyi, Nantong, Shanghai, Shenzhen, Shijiazhuang, Taiyuan, Wuhan, Xuzhou, Zhengzhou
Age
18 years and over
People
170
Run by
Xynomic Pharmaceuticals, Inc.
See details and how to joinNCT03936153
Phase 1/2Taking people
Safety and Efficacy of R-CMOP Versus R-CHOP in the Initial Treatment of DLBCL
Where
Beijing, Fuzhou, Ganzhou, Guangzhou, Guilin, Lanzhou, Nanchang, Shenzhen, Zhuhai
Age
18 years to 80 years
People
112
Run by
Sun Yat-sen University
See details and how to joinNCT06760039
Phase 1/2Taking people
Safety and Efficacy of Early Second Infusion of Axi-cel Based on ctDNA for R/R Large B - Cell Lymphoma
Where
Guangzhou
Age
18 years and over
People
15
Run by
Zhujiang Hospital
See details and how to joinNCT06902012
Phase 2Taking people
Clinical Trial of TQB2825 Injection Combined With Chemotherapy in Subjects With Diffuse Large B-cell Lymphoma
Where
Changsha, Chengdu, Dalian, Guangzhou, Hangzhou, Harbin, Jinan, Lanzhou, Luzhou, Nanchang, Nanjing, Nanning, Shijiazhuang, Suzhou, Taiyuan, Weihai, Wuhan, Wuhu, Xiamen, Xi’an, Zhengzhou
Age
18 years and over
People
55
Run by
Shanghai Chia Tai Tianqing Pharmaceutical Technology Development Co., Ltd.
See details and how to joinNCT06854445
Phase 2Not yet taking people in China
Zanubrutinib, Chidamide, and Rituximab Induction With or Without CHOP Versus R-CHOP in Newly Diagnosed Double-Expressor DLBCL
Where
Guangzhou
Age
18 years to 65 years
People
128
Run by
Li Zhiming
See details and how to joinNCT06890585
Phase 2Taking people
Chidamide Plus R-CHOP in Newly Diagnosed Double-Expressor Diffuse Large B-Cell Lymphoma With Other Molecular Subtypes
Where
Nanjing
Age
18 years and over
People
148
Run by
The First Affiliated Hospital with Nanjing Medical University
See details and how to joinNCT06891157
Phase 2Taking people
CHiR Therapy for Elderly DLBCL Intolerant to Chemo
Where
Ningbo
Age
70 years to 100 years
People
30
Run by
First Affiliated Hospital of Ningbo University
See details and how to joinNCT06764017
Phase 2Taking people
Clinical Study of HiR+X Therapy for Newly Diagnosed Elderly Patients With DLBCL Intolerant to Chemotherapy
Where
Ningbo
Age
70 years to 100 years
People
50
Run by
First Affiliated Hospital of Ningbo University
See details and how to joinNCT06758037
Phase 1/2Taking people
A Study of RNK05047 in Subjects With Advanced Solid Tumors/Diffuse Large B-cell Lymphoma (CHAMP-1)
Where
Beijing
Age
18 years and over
People
32 worldwide
Run by
Ranok Therapeutics (Hangzhou) Co., Ltd.
See details and how to joinNCT05487170